Literature DB >> 8625442

Changes in O6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts.

L C Harris1, M A von Wronski, C C Venable, J S Remack, S R Howell, T P Brent.   

Abstract

Suppressed expression of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT), characterized as the Mer- phenotype, occurs only in malignant or transformed cell lines. To investigate the relationship between the transformation process and loss of MGMT expression, we derived 20 cloned lines of IMR90 normal fibroblasts transfected with the plasmid pSV3neo expressing the SV40 large-T antigen. Of the five lines that were grown until crisis phase, four emerged as continuously proliferating immortal lines. Of these, only one retained MGMT, the other three having become Mer-. In every case the loss of MGMT coincided with the final phase of immortalization following crisis. Because these were cloned cell lines it is clear that the phenotypic change to Mer- is not merely due to selection of a Mer- cell from the initial population, but must involve a cellular change in MGMT regulation. It is not clear if increased mutation rate associated with loss of MGMT results in increased frequency of an immortalization event or if an immortalization event, such as telomere disruption, results in MGMT suppression. In addition, we have shown that, consistent with previous observations, both hypermethylation in promoter sequences and hypomethylation of downstream sequences in the body of the gene were closely associated with loss of MGMT expression. These studies also illustrate the utility of these new cloned cell lines for characterizing molecular events associated with transformation and immortalization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625442     DOI: 10.1093/carcin/17.2.219

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

Review 1.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

2.  Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.

Authors:  Kimiko Ishiguro; Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

3.  A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.

Authors:  Murali M Chintagumpala; Henry S Friedman; Clinton F Stewart; James Kepner; Roger E McLendon; Paul L Modrich; Charles McCluggage; Peter Burger; Emi Holmes; Stephen Thompson; James Rutka; Jeff Michalski; Shiao Woo; Susan M Blaney; Larry E Kun; Marc E Horowitz
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

4.  Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein.

Authors:  Kimiko Ishiguro; Krishnamurthy Shyam; Philip G Penketh; Alan C Sartorelli
Journal:  Anal Biochem       Date:  2008-08-20       Impact factor: 3.365

5.  Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.

Authors:  Wenjia Guo; Hailong Tian; Xiaogang Dong; Jinping Bai; Xinling Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

6.  Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.

Authors:  Thushara Chakkath; Sidonie Lavergne; Timothy M Fan; David Bunick; Levent Dirikolu
Journal:  Vet Sci       Date:  2015-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.